In this study, we identified five miRNAs highly expressed in the small-cell lung cancer (SCLC) cell line NCI-H209. Among them, the expression levels of miR-375 were dramatically elevated in all SCLC cell lines examined, coincident with the expression of the transcription factor achaete-scute complex homolog 1 (ASCL1). Moreover, miR-375 was upregulated and correlated with ASCL1 in the cell lines generated from mouse SCLC-like tumors as well. Dual-luciferase assays further showed that ASCL1 activated the expression of miR-375 by binding to the three E-box elements in the miR-375 promoter. These results imply a role of ASCL1 in SCLC via the upregulation of miR-375.
Introduction
Lung cancer is one of the most lethal cancers worldwide. Based on the clinicopathologic characteristics, lung cancer can be divided into two major groups: small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC). SCLC is highly aggressive and malignant, accounting for 15% of all cases of lung cancer. It mainly arises in the larger airways and grows fast with early widespread metastases [1, 2] . Despite a good response of SCLC to initial chemotherapy, its late detection and frequent relapses still lead to a low survival rate. Overall, only ,10% of SCLC patients survive beyond 5 years [1] . Current diagnosis of SCLC is made primarily on light microscopic examination and computed tomography scan [1] . Identification of early diagnostic biomarkers would thus improve the early-stage diagnosis of SCLC and the reduction of its high mortality.
The most noticeable characteristic of SCLC is the expression of neuronal and neuroendocrine (NE) markers, such as NCAM, snap25, and synaptophysin, which are not frequently seen in NSCLC [3] [4] [5] . Achaete-scute complex homolog 1 (ASCL1, also named ASH1), a bHLH transcription factor, a key factor in the early development of neurons and several types of NE cells [6, 7] , is required for the expression of NE markers and plays a critical role in the onset of SCLC [8, 9] . Constitutive expression of ASCL1 induces airway epithelia cell over-proliferation and enhances tumorigenesis in SV40 large T antigen transgenic mice, in which the large T antigen inhibits tumor suppressors p53 and retinoblastoma (Rb). Consistently, RNAi knockdown of ASCL1 significantly suppresses lung cancer cell growth both in vivo and in vitro [8] .
MicroRNAs (miRNAs) are 22-nucleotide non-coding RNAs that regulate gene expression post-transcriptionally and play important roles in numerous biological and pathological processes including tumorigenesis, development, aging, and cell differentiation [10 -13] . With the aid of high-throughput profiling methods, numerous miRNAs that are differentially expressed between tumor samples and paracancerous histopathological normal tissues have been identified and several as oncogenes or tumor suppressors [14, 15] . For instance, the miR-17-92 cluster, whose expression is directly transactivated by c-Myc, promotes tumorigenesis by targeting the cyclin-dependent kinase inhibitor p21 and the pro-apoptotic gene BIM [16] [17] [18] [19] . Distinct from the miR-17-92 cluster, let-7 is downregulated in many tumors because it inhibits cancer cell growth by suppressing two oncogenes, K-Ras and c-Myc [20, 21] .
In this study, we reported that the expression levels of miR-375 were highly upregulated probably by ASCL1 in SCLC cell lines.
Materials and Methods
Cell culture SCLC cell lines (NCI-H69, H82, H209, and H345; kindly provided by Dr Z. Chen, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China); NSCLC cell line CRL 5908 and normal human bronchial epithelial cell line Beas-2B; mouse SCLC cell lines R913, R415, R716T1, R716 T2-A, R732, R716 T2-S, and R716 LN isolated from the tumors in Rb 2/2 p53 2/2 mice, were maintained in RPMI 1640 supplemented with 10% fetal bovine serum (FBS), 100 IU/ml of penicillin, and 100 mg/ml of streptomycin at 378C and 5% CO 2 . HEK293T cells were cultured in Dulbecco's modified Eagle's medium with 10% FBS, 100 IU/ml of penicillin, and 100 mg/ml of streptomycin.
Microarray hybridization and data analysis
To screen for highly expressed miRNAs in SCLC cells, total RNAs from NCI-H209 (SCLC) or CRL 5908 (NSCLC) cells were subjected to mParaflo w microRNA microarray assay through a contracted service (LC Sciences, Hangzhou, China). Briefly, 2-5 mg total RNAs were size fractioned with the YM-100 microcon centrifugal filter (Millipore, Billerica, USA). The small RNAs (,300 nt) were isolated and added poly(A) tails using poly(A) polymerase. An oligonucleotide tag was ligated to the poly(A) tail for fluorescent dye staining. Hybridization was performed overnight on a mParaflo microfluidic chip using a micro-circulation pump (Atacti Technologies, Houston, USA). Tag-specific Cy5 dyes were used for the fluorescence labeling after hybridization. The images were collected using GenePix 4000B (Molecular Device, San Jose, USA) and were analyzed using Array-Pro image analysis software (Media Cybernetics, Bethesda, USA).
Plasmid constructs
The full-length ASCL1 cDNA was amplified by reverse transcriptase-polymerase chain reaction (RT-PCR) from NCI-H345 cells and subcloned into pcDNA3.1-NFlag vector, to express Flag-ASCL1. Plasmids for promoter activity measurements were constructed using pGL4.17 vector. The region 1.5 kb upstream to the miR-375 gene was amplified from NCI-H345 genomic DNA. The primers used to generate the plasmids of wild type and mutants of miR-375 promoter are listed in Table 1 .
Quantitative RT-PCR Total RNA was extracted from the cultured cells using miRVana TM miRNA isolation kit (Ambion, Austin, USA) according to the manufacturer's instructions. miRNA reverse transcription and PCR reactions were performed as previously described with some modifications [22] . Briefly, 100 ng of total RNAs were reverse-transcribed with 50 nM of stem-loop RT primers in 15 ml reaction volume. The reactions were incubated for 30 min at 168C, 30 min at 428C and 5 min at 858C according to the user manual (Cat. 4366597; Applied Biosystems, Foster City, USA). SYBR green real-time PCR assays were performed in 20 ml PCR reactions containing 1 ml RT products, 1 Â Power SYBR Green Master Mix (Cat. 4367659; Applied Biosystems) and 0.5 mM forward/reverse primers. The reactions were incubated at 958C for 10 min, followed by 40 cycles of 15 s at 958C and 1 min at 608C. The relative expressions of miRNAs were normalized with U6. Primers used in these experiments are listed in Table 1 . miR-375 TaqMan miRNA assay kit was purchased from Applied Biosystems (Cat. 4427975). The PCR assay was performed according to the user's manual.
Luciferase assays
HEK293T cells were transfected with Luc reporter plasmids containing the promoter region of miR-375 or its corresponding mutants, Renilla luciferase plasmid, and FLAG-ASCL1 plasmid or the vector. After 24 h, the cells were lysed and luciferase activities were measured with Dual-Luciferase Reporter Assay System (Promega, Madison, USA).
Results and Discussion
From a miRNA microarray assay with SCLC cell line H209 and NSCLC cell line CRL 5908, we identified five miRNAs (miR-95, miR-200a, miR-200b, miR-335, and miR-375) with enhanced expression in H209 cells. Subsequent SYBR green real-time PCR (qPCR) on NCI-H209 and CRL 5908 cells confirmed the microarray results (Fig. 1) . To examine whether the upregulation of the five microRNAs were specific for SCLC cell lines, we further examined their expression patterns in other SCLC cell lines (H69, H82, and H345) and one immortalized human lung epithelial cell line, Beas-2B [ Fig. 2(A) ] and found that miR-375 was consistently upregulated in all four SCLC cell lines. The elevated expression of miR-375 in SCLC cell lines was also confirmed by TaqMan-based real-time PCR [ Fig. 2(B) ]. Moreover, miR-375 was also the microRNA with the strongest upregulation in SCLC cell lines compared with CRL 5908 and Beas-2B cells [ Fig. 2(A) ]. Strikingly, miR-375 expression in SCLC cell lines, H209 and H345, increased by .8000 folds in comparison with Beas2B [ Fig. 2(A) ]. Furthermore, the expression of miR-375 was highly correlated with ASCL1, a transcription factor modulating tumorigenicity in SCLC, in all four tested SCLC cell lines [ Fig. 2(A) ].
We next examined whether miR-375 is also related to SCLC in vivo. Because SCLC is rarely surgically resected, especially at the early stage, SCLC samples are very difficult to obtain. It is known that conditional knockout of p53 and Rb in mouse lung epithelial cells induces human SCLC-like tumors (mSCLCs). Such a mouse model provides a convenient and useful tool for SCLC studies [23] .
High-level expression of miR-375 in SCLC Therefore, seven cell lines generated from mSCLC tumors were used to examine the correlation of miR-375, ASCL1 and SCLC in vivo. Interestingly, miR-375 was highly expressed in four of them and ASCL1 also showed similar expression patterns (Fig. 3) .
A previous study showed that three bHLH transcription factor-binding sites, E-boxes, are located within the promoter region of miR-375 (from 2370 to 290 upstream of the hairpin of miR-375) [ Fig. 4(A) ] [24] . Because ASCL1 is a bHLH transcription factor and coincided with miR-375 Figure 3 The expressions of ASCL1 and miR-375 are highly correlated in mSCLC cell lines Total RNA was extracted from the cell lines generated from the tumors in Rb 2/2 p53 2/2 mice and qRT-PCR was performed. The miRNA expression levels were normalized to the levels of U6, whereas the levels of ASCL1 were normalized to those of GAPDH. We thus investigated whether ASCL1 could activate a luciferase reporter driven by miR-375 promoter (375p-LUC). Indeed, the luciferase activity in HEK293T cells increased by around 6 folds in the presence of Flag-ASCL1 [ Fig. 4(B) ]. To map the binding sites of ASCL1 in the miR-375 promoter, point mutations were introduced in the three E-box sites in 375p-LUC to generate a series of mutants [ Fig. 4(A) ]. Luciferase assays revealed that mutation of any single E-box site significantly reduced transactivation activity of ASCL1 on miR-375 promoter. Moreover, the reporter with all three sites mutated exhibited only basal level luciferase activity [ Fig. 4(B) ]. These data suggest that ASCL1 regulates miR-375 expression through the three E-boxes. During the revision of this manuscript, Nishikawa et al. [25] reported transcription of miR-375 by ASCL1 in lung cancers with NE features and demonstrated a critical role of miR-375 in ASCL1-induced NE features by targeting YAP1, a transcription co-activator. miR-375 appears to play a multifaceted role in different cancers. In addition to SCLC, its altered expression has also been documented in other types of cancers. In breast and prostate cancers, its upregulation stimulates cell proliferation by targeting Sec23A and RASD1, respectively [26, 27] , whereas its downregulation in gastric cancer leads to the activation of PDK1-Akt and JAK oncogenic pathways [28, 29] . Therefore, miR-375 may promote or inhibit tumor progression depending on different contexts of cancer cells.
SCLC is an aggressive and metastatic tumor, leading to a high mortality. Since SCLC is sensitive to the chemotherapy, the convenient and early diagnosis may help to decrease the mortality of SCLC patients [1] . Recently, alterations in serum/plasma miRNA levels between cancer patients and healthy persons have been reported to serve as diagnostic biomarkers for cancer detections [30, 31] . If miR-375 also showed unusual high-expression levels in SCLC, as in SCLC cell lines (Figs. 1-3 ) [25] , it might be easily detected in the sera of SCLC patients and could thus serve as a good marker for early and efficient diagnosis of SCLC. 
